High Dose (15mg/15mg) Designed for chronic injuries, surgical rehab, or multi-site conditions
Animal Toxicology Studies Animal toxicology studies tested doses from 0.0027 mg/lb to 9.1 mg/lb via intraperitoneal, intramuscular, intravenous, and oral routes for up to 6 weeks, finding: No acute toxic or lethal dose No gross or histologic toxicity in major organs No hepatotoxicity or nephrotoxicity Negative Ames test (no mutagenicity) Negative chromosomal aberration tests (no genotoxicity) No teratogenicity in rat pregnancy studies No local injection site irritation The LD1 (minimum lethal dose) could not be achieved despite aggressive testing
Best Practices for Storing and Handling GHK-Cu Research Peptide: Stability in Lab Settings This article is part of our comprehensive GHK-Cu Research Peptide Complete Guide
Cells were first stained with 50 M DCFDA or 10 M mBcl, as described above, followed by a washing step with PBS and a surface staining of 30 min on ice with combinations of the following monoclonal antibodies: PE-conjugated anti-CD10 (HI10), PerCP-conjugated anti-CD3 (SK7), APC-conjugated anti-CD19 (SJ25C1), PE-conjugated anti-CD5 (L17F12), PE-conjugated anti-CD25 (PC61), all from BD Biosciences
This is also one of the core objectives in previous clinical trials such as the observational studies on the association between riboflavin synthesis genes and type 2 diabetes using metagenomics 156 and the ongoing clinical trial with the riboflavin-overproducing strain L